Guardant Health, Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
GH$155.35-2.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
Condensed Consolidated Statements of Stockholders’ Deficit (unaudited)
(in thousands, except share data)
| Three Months Ended March 31, 2026 | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Deficit | ||||||
| Shares · Amount | ||||||
| Balance as of January 1, 2026 | 130,635,301 | $1 | $2,900,056 | $(4,852) | $(2,994,512) | $(99,307) |
| Issuance of common stock upon exercise of stock options | 111,329 | — | 3,651 | — | — | 3,651 |
| Vesting of restricted stock units | 767,774 | — | — | — | — | — |
| Employee taxes paid related to net share settlement of restricted stock units | — | — | (20,650) | — | — | (20,650) |
| Stock-based compensation | — | — | 47,608 | — | — | 47,608 |
| Other comprehensive loss | — | — | — | (300) | — | (300) |
| Net loss | — | — | — | — | (112,075) | (112,075) |
| Balance as of March 31, 2026 | 131,514,404 | $1 | $2,930,665 | $(5,152) | $(3,106,587) | $(181,073) |
| Three Months Ended March 31, 2025 | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Additional Paid-in Capital · Accumulated Other Comprehensive Loss · Accumulated Deficit · Total Stockholders’ Deficit | |||||||
| Shares · Amount · Treasury Stock | |||||||
| Balance as of January 1, 2025 | 123,994,006 | $1 | $— | $2,443,788 | $(5,201) | $(2,578,235) | $(139,647) |
| Issuance of common stock upon exercise of stock options | 44,121 | — | — | 768 | — | — | 768 |
| Vesting of restricted stock units | 585,390 | — | — | — | — | — | — |
| Employee taxes paid related to net share settlement of restricted stock units | — | — | — | (15,497) | — | — | (15,497) |
| Stock-based compensation | — | — | — | 37,757 | — | — | 37,757 |
| Repurchase of treasury stock | (976,351) | — | (45,010) | — | — | — | (45,010) |
| Unwinding of convertible note hedges | — | — | — | 5,456 | — | — | 5,456 |
| Other comprehensive income | — | — | — | — | 543 | — | 543 |
| Net loss | — | — | — | — | — | (95,159) | (95,159) |
| Balance as of March 31, 2025 | 123,647,166 | $1 | $(45,010) | $2,472,272 | $(4,658) | $(2,673,394) | $(250,789) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.